Acute Myeloid Leukemia in Remission

Known as: Acute Myeloblastic Leukemia in Remission, Acute Granulocytic Leukemia in Remission, Acute myeloid leukemia, in remission 
Acute myeloid leukemia not growing, responding to treatment.
National Institutes of Health

Related topics

Related topics

4 relations
Hematopoietic and Lymphoid CellHematopoietic and Lymphoid TissueHemopoietic tissueLeukemia, Myelocytic, Acute

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study.
The effects of HLA-identical sibling donor (ISD) hematopoietic stem cell transplantation (HSCT) on adults with intermediate- or… Expand
  • table 1
  • figure 1
  • figure 1
  • table 2
Is this relevant?
2015
2015
Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission
The optimal intensity of conditioning for allogeneic hematopoietic stem cell transplantation (HCT) in acute myeloid leukemia (AML… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2014
2014
Results of a Phase 1 Study of Quizartinib (AC220) As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Cell Transplantation
FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) in acute myeloid leukemia (AML) are associated with early… Expand
Is this relevant?
2013
2013
Impact of pretransplantation risk factors on post transplantation outcome of patients with acute myeloid leukemia in remission after haploidentical hematopoietic stem cell transplantation.
The impact of risk-related parameters has not been defined in transplantation settings. We wondered whether the currently… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2006
2006
Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.
Relapse is a major obstacle in the cure of acute myeloid leukemia (AML). The Pediatric Oncology Group AML Study 9421 tested 2… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
1997
1997
Prognostic value of metaphase-fluorescence in situ hybridization in follow-up of patients with acute myeloid leukemia in remission.
The presence of residual leukemic cells was studied using metaphase-fluorescence in situ hybridization (FISH) in 22 patients with… Expand
  • table 1
  • figure 1
Is this relevant?
Highly Cited
1990
Highly Cited
1990
Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma.
We analyzed the relevance of HLA incompatibility to acute graft-versus-host disease, relapse, and survival in 281 patients with… Expand
Is this relevant?
1987
1987
Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia.
A pilot study was conducted to determine the possible efficacy and the toxicities associated with the administration of four… Expand
Is this relevant?
1984
1984
Deficiency of erythrocyte superoxide dismutase and catalase activities in patients with malignant lymphoma and acute myeloid leukemia.
The activity of erythrocyte superoxide dismutase (SOD) and catalase was determined in 38 patients with lung cancers (n = 15… Expand
Is this relevant?
1982
1982
A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
1-beta-D-Arabinofuranosylcytosine (ara-C), 2 or 3 g/sq m, was administered as a 1-hr i.v. infusion every 12 hr for 10 or 12 doses… Expand
Is this relevant?